Company Description
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.
It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders.
The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Adi Zuloff-Shani |
Contact Details
Address: 1220 West 6th Avenue, Suite 101 Vancouver, BC V6H 1A5 Canada | |
| Phone | 604 260 1566 |
| Website | clearmindmedicine.com |
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001892500 |
| ISIN Number | CA1850534027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer |
| Prof. Mark Haden M.S.W. | Vice President of Business Development |
| Gilad Babchuk | Head of Strategy and Communication |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | EFFECT | Notice of Effectiveness |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Sep 24, 2024 | POS AM | Post-Effective amendments for registration statement |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | 6-K | Report of foreign issuer |
| Sep 12, 2024 | 6-K | Report of foreign issuer |
| Sep 6, 2024 | 6-K | Report of foreign issuer |